intedanib the game changer in COVID 19 patients
Phase 3
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/07/035256
- Lead Sponsor
- Self
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Without any comorbidities
Exclusion Criteria
Diabetes, hypertension, IHD, CKD, immunosuppressive status, old age
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We are collecting the samples by taking into consideration of rtpcr positivity in covid patients and we will assess the inhospital mortality and prognosis of patients during there hospital stayTimepoint: 4 to 6 weeks
- Secondary Outcome Measures
Name Time Method To asses the prognosis in COVID 19 patients who had taken the drugTimepoint: 10th day from the day of administration of the drug